TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

Michelle A Kelliher; Katherine A Fitzgerald

doi:10.1016/j.it.2023.01.009

TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

Trends Immunol. 2023 Mar;44(3):156-158. doi: 10.1016/j.it.2023.01.009. Epub 2023 Feb 4.

Authors

Michelle A Kelliher¹, Katherine A Fitzgerald²

Affiliations

¹ Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, University of Massachusetts, Worcester, MA, USA.
² Division of Innate Immunity, University of Massachusetts Chan Medical School, University of Massachusetts, Worcester, MA, USA. Electronic address: kate.fitzgerald@umassmed.edu.

PMID: 36740513
DOI: 10.1016/j.it.2023.01.009

Abstract

Resistance mechanisms have curbed the potential of immune checkpoint blockade (ICB) therapies. Understanding mechanisms that contribute to this resistance should reveal new targets for combinatorial therapy. Tank-binding kinase 1 (TBK1) represents such a target. In recent work by Sun et al., inhibition of TBK1 restored the efficacy of such treatments by sensitizing tumors to RIPK1 kinase-dependent inflammatory cell death.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Cell Death
Humans
Immunotherapy
Neoplasms*
Protein Serine-Threonine Kinases
Receptor-Interacting Protein Serine-Threonine Kinases

Substances

RIPK1 protein, human
Receptor-Interacting Protein Serine-Threonine Kinases
TBK1 protein, human
Protein Serine-Threonine Kinases

Abstract

Publication types

MeSH terms

Substances

Grants and funding